About $575 million came in for Viking Therapeutics, including $258.75 million in debt that can turn into shares.

Viking Therapeutics (VKTX) closed upsized offerings of 9.04M shares at $35.00 and $258.75M of 2.00% convertible notes due 2032, raising ~$575M gross. The company plans to use proceeds for late-stage obesity programs, according to the press release.

Viking Therapeutics (VKTX) closed upsized offerings of 9,035,714 shares at $35 each and $258.75M in convertible notes, raising $575M gross. Proceeds will fund clinical development, including VK2735 and VK3019 programs, and general corporate purposes.

Viking Therapeutics (VKTX) reported strong clinical data for its obesity drug VK2735, with patients maintaining significant weight loss during maintenance dosing. The company is progressing with Phase 3 trials and plans to start a study for an oral formulation. However, Viking reported a net loss of $128.1 million in Q2 2026 and has been burning cash rapidly, with $501.7 million in total cash and short-term investments as of June 30, 2026.

Viking Therapeutics (VKTX) reported positive maintenance trial results for its obesity drug VK2735, leading to a share price surge. The company plans to raise $500 million to support drug development. While subcutaneous results are promising, oral formulation data remains uncertain. CEO Brian Lian noted adjustments to Phase 3 trials to improve tolerability.

Viking Therapeutics (VKTX) reported positive results from a maintenance study of its obesity drug VK2735, showing 22% weight loss and sustained maintenance. The company raised $500M in capital. Wall Street upgraded the stock.

Viking Therapeutics (VKTX) shares rose 18.10% in a week due to progress in its obesity drug VK2735, now in Phase 1 trials. The company raised $225 million via a secondary offering, signaling investor confidence. VK2735 is being tested in both injectable and oral forms, with potential to compete in the obesity drug market.